Steve P. Jones

Hospira Adelaide Pty Ltd. engages in the provision of biotechnology and research services. It also develops cell therapy technology. It offers biopharmaceutical API products including hGH, a treatment for human growth hormone deficiency; G-CSF, which is used in the treatment of leukemia; and Interferon alpha for chronic hepatitis B and C. The company was founded in 1982 and is headquartered in Thebarton, Australia.

PricewaterhouseCoopers LLC provides assurance, tax and advisory services. Its services include audit and assurance, consulting, deals, human resources, legal, tax, and family business. The firm also offers accountability, risk management, structuring, mergers and acquisitions, and performance and process improvement. The company was founded in 1998 and is headquartered in Buffalo, NY.

CBio Ltd. focuses on developing new generation products for the treatment of autoimmune and inflammatory diseases. It develops and commercializes treatments for autoimmune diseases. The company focuses and develops technologies on commercializing its proprietary drug, XToll for autoimmune and inflammatory diseases. It develops technologies for the treatment of autoimmune and inflammatory diseases. The company also engages in the business of research, product development and clinical trials of the therapeutic drug XToll and development of variants to the company's Cpn10 technology. CBio was founded by Steve P. Jones on October 11, 2000 and is headquartered at Brisbane, Australia.

Analytica Ltd. engages in the design development, and supply of class 1 and class 2 medical devices. It operates through the following segment: Medical Devices and Corporate. The Medical Devices segment is consist of AutoStart Burette, PeriCoach, and ELF 2. The Corporate segment includes all other operations including the administration, and associated listed public company expenditure. The company is headquartered in Brisbane, Australia.

Viralytics Pty Ltd. engages in the development and commercialization of oncolytic immunotherapies that harness the power of certain viruses to infect and kill cancer cells. Its product, CAVATAK, is a genetically unmodified proprietary formulation of the common cold Coxsackievirus Type A21. The company was founded in 1984 and is headquartered in Sydney, Australia.